Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1

NCT02588131 is registered in ClinicalTrials.gov with Italian Network for Tumor Biotherapy Foundation as lead sponsor.

NCT NCT02588131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02588131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1
Lead sponsor
Italian Network for Tumor Biotherapy Foundation
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2015
Completion date
March 31, 2018
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal mesothelioma, pleural mesothelioma